Oncoloxía médica
Servizo
Hospital Universitario de Jaén
Jaén, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de Jaén (26)
2024
2022
2021
-
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial
Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56
-
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry
PLoS ONE, Vol. 16, Núm. 6 June
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
-
Real-life use of ramucirumab in gastric cancer in Spain: The RAMIS study
Future Oncology, Vol. 17, Núm. 14, pp. 1777-1791
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Lung Cancer, Vol. 150, pp. 62-69
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study
BMC Cancer, Vol. 18, Núm. 1
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2016
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
2014
-
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 160-166